Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. PureTech Health's annualizedNet Income for the quarter that ended in Dec. 2025 was £-97.31 Mil. PureTech Health's average total tangible assets for the quarter that ended in Dec. 2025 was £403.14 Mil. Therefore, PureTech Health's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -24.14%.
The historical rank and industry rank for PureTech Health's Return-on-Tangible-Asset or its related term are showing as below:
LSE:PRTC'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -19.07 Med: -6.37 Max: 60.39
Current: -19.07
During the past 13 years, PureTech Health's highest Return-on-Tangible-Asset was 60.39%. The lowest was -19.07%. And the median was -6.37%.
LSE:PRTC's Return-on-Tangible-Asset is ranked better than 63.06% of 1416
companies
in the Biotechnology industry
Industry Median: -35.76
vs LSE:PRTC: -19.07
PureTech Health (LSE:PRTC) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
PureTech Health Return-on-Tangible-Asset Related Terms
PureTech Health Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for PureTech Health's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:PRTC vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, PureTech Health's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where PureTech Health's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -24.14% mean?
PureTech Health (LSE:PRTC) has a Return-on-Tangible-Asset of -24.14% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PureTech Health and its competitors. According to the industry distribution chart, PureTech Health ranks #523 out of 1416 companies in the Biotechnology industry, placing it in the top 36.9%.
Is PureTech Health's Return-on-Tangible-Asset too high?
PureTech Health's current Return-on-Tangible-Asset is -24.14%. Based on the distribution chart, PureTech Health ranks #523 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PureTech Health has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #523 out of 1416 companies for Return-on-Tangible-Asset. This puts PureTech Health in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PureTech Health and its competitors. PureTech Health's current Return-on-Tangible-Asset is -24.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (LSE:PRTC) is currently considered Possible Value Trap. The stock's GF Value™ is £5.31, compared to a current price of £1.20 — trading 77.4% below its estimated fair value. The current Return-on-Tangible-Asset is -24.14%. PureTech Health's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For PureTech Health (LSE:PRTC), the current Return-on-Tangible-Asset is -24.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (LSE:PRTC) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of £1.20 is trading 77.4% below its estimated GF Value™ of £5.31.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for LSE:PRTC:
Return-on-Tangible-Asset: -24.14%
GF Value™: £5.31 vs. price of £1.20 (77.4% below fair value)
No single metric tells the full story. See the LSE:PRTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
63GF Score
Get the complete analysis for LSE:PRTC
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:PRTC has been successfully added to your 
